Head-To-Head Survey: Genfit (NASDAQ:GNFT) versus Neurocrine Biosciences (NASDAQ:NBIX)

Genfit (NASDAQ:GNFTGet Free Report) and Neurocrine Biosciences (NASDAQ:NBIXGet Free Report) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, dividends, earnings and analyst recommendations.

Risk and Volatility

Genfit has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500. Comparatively, Neurocrine Biosciences has a beta of 0.25, meaning that its share price is 75% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings for Genfit and Neurocrine Biosciences, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Genfit 0 0 2 0 3.00
Neurocrine Biosciences 0 6 17 0 2.74

Genfit currently has a consensus target price of $11.00, indicating a potential upside of 208.99%. Neurocrine Biosciences has a consensus target price of $137.92, indicating a potential upside of 0.00%. Given Genfit’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Genfit is more favorable than Neurocrine Biosciences.

Insider and Institutional Ownership

2.2% of Genfit shares are held by institutional investors. Comparatively, 92.6% of Neurocrine Biosciences shares are held by institutional investors. 4.2% of Genfit shares are held by insiders. Comparatively, 4.4% of Neurocrine Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.


This table compares Genfit and Neurocrine Biosciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Genfit N/A N/A N/A
Neurocrine Biosciences 13.23% 12.85% 9.02%

Valuation and Earnings

This table compares Genfit and Neurocrine Biosciences’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Genfit $28.00 million 6.34 -$24.99 million N/A N/A
Neurocrine Biosciences $1.89 billion 7.27 $249.70 million $2.42 56.99

Neurocrine Biosciences has higher revenue and earnings than Genfit.


Neurocrine Biosciences beats Genfit on 9 of the 12 factors compared between the two stocks.

About Genfit

(Get Free Report)

Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.

About Neurocrine Biosciences

(Get Free Report)

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Receive News & Ratings for Genfit Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genfit and related companies with MarketBeat.com's FREE daily email newsletter.